Yana Chernoryzh

Yana Chernoryzh

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2019 in Fullerenes, Nanotubes and Carbon Nanostructures
Verified
Journal Article
Closed access
RKRegina Klimova
Regina Klimova
SASergey M Andreev
Sergey M Andreev
EMEkaterina Momotyuk
Ekaterina Momotyuk
NDNatalia Andreevna Demidova
Natalia Andreevna Demidova
NFNatalia Fedorova
Natalia Fedorova
AGAlexander Gintsburg
Alexander Gintsburg
Fullerene C60 is known as a promising therapeutic agent due to its antioxidant, anti-inflammatory and other properties, along with the lack of noticeable toxicity. In this article, we describe antiviral properties of aqueous fullerene C60 dispersion (ndC60) produced by biocompatible diafiltration technology and C60 amino derivatives against Herpes simplex virus type 1 (HSV-1) and Human cytomegalovirus (HCMV) infections. Their activity in vitro was evaluated by a plaque reduction assay using Vero and HF cells in pre- and post-treatment modes. Therapeutic efficacy of dnC60 and C60 derivatives was studied in DBA mice using cutaneous model of HSV-1 infection. Data obtained indicated low cytotoxicity of all used compounds for both cell lines (CC50 > 1 mg/ml). The antiviral activity of dnC60 in most tests exceeded the activity of both C60 amino adducts and acyclovir (ACV), and it demonstrated significant therapeutic effect against HSV-1 skin infection in mice.

26 January 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Gleb PetrovGleb Petrov
Gleb Petrov
Daria Alexandrovna GalkinaDaria Alexandrovna Galkina
Daria Alexandrovna Galkina
Alena KoldinaAlena Koldina
Alena Koldina
Tatiana Vladimirovna GrebennikovaTatiana Vladimirovna Grebennikova
Tatiana Vladimirovna Grebennikova
OEOlesya V. Eliseeva
Olesya V. Eliseeva
Anton SyroeshkinAnton Syroeshkin
Anton Syroeshkin
Previous studies have shown that complexly shaped nanoparticles (NPs) have their intrinsic radiothermal emission in the millimeter range. This article presents a method for controlling the quality of nanodrugs—immunobiological preparations (IBPs)—based on the detection of their intrinsic radiothermal emissions. The emissivity of interferon (IFN) medicals, determined without opening the primary package, is as follows (µW/m2): IFN-α2b—80 ± 9 (105 IU per package), IFN-β1a—40 ± 5 (24 × 106 IU per package), IFN-γ—30 ± 4 (105 IU per package). The emissivity of virus-like particles (VLP), determined using vaccines Gam-VLP-multivac (120 μg) in an injection bottle (crimp cap vials), was as follows: 12 ± 1 µW/m2, Gam-VLP—rota vaccines—9 ± 1 µW/m2. This study shows the reproducibility of emissivity over the course of a year, subject to the storage conditions of the immunobiological products. It has been shown that accelerated aging and a longer shelf life are accompanied by the coagulation of active NPs, and lead to a manyfold drop in emissivity. The dependence of radiothermal emission on temperature has a complex, non-monotonic nature. The emission intensity depends on the form of dosage, but remains within the order of magnitude for IFN-α2b for intranasal aqueous solution, ointments, and suppositories. The possibility of the remote quantitative control of the first phases of the immune response (increased synthesis of IFNs) to the intranasal administration of VLP vaccines has been demonstrated in experimental animals.

7 November 2023 in Problems of Virology
Verified
Journal Article
Open access
PDF file
LKLudmila V. Kostina
Ludmila V. Kostina
IFIlya E. Filatov
Ilya E. Filatov
OEOlesya V. Eliseeva
Olesya V. Eliseeva
OLOleg E. Latyshev
Oleg E. Latyshev
YCYana Chernoryzh
Yana Chernoryzh
ЦВЦибезов Валерий Владимирович
Цибезов Валерий Владимирович
Introduction. In Russia, almost half of the cases of acute intestinal infections of established etiology in 2022 are due to rotavirus infection (RVI). There is no specific treatment for rotavirus gastroenteritis. There is a need to develop modern, effective and safe vaccines to combat rotavirus infection that are not capable of multiplying (replicating) in the body of the vaccinated person. A promising approach is to create vaccines based on virus-like particles (VLPs). Objective. Study of the safety and immunogenicity of a vaccine against rotavirus infection based on virus-like particles of human rotavirus A in newborn minipigs with multiple intramuscular administration. Materials and methods. Newborn minipigs were used as an animal model in this study. The safety of the tested vaccine was assessed based on thermometry data, clinical examination, body weight gain, clinical and biochemical blood parameters, as well as necropsy and histological examination. When studying the immunogenic properties of the Gam-VLP-rota vaccine in doses of 30 and 120 µg, the cellular, humoral and secretory immune response was studied. Results. The results of assessing the general condition of animals during the immunization period, data from clinical, laboratory and pathomorphological studies indicate the safety of the vaccine against human rotavirus infection based on VLP (Gam-VLP-rota) when administered three times intramuscularly. Good local tolerance of the tested vaccine was demonstrated. The results of the assessment of humoral immunity indicate the formation of a stable immune response after three-time immunization with Gam-VLP-rota, stimulation of the production of antigen-specific IgG antibodies and their functional activity to neutralize human rotavirus A. It was shown that following the triple immunization with the minimum tested concentration of 30 µg/dose, animals developed a cell-mediated immune response. The results of the IgA titer in blood serum and intestinal lavages indicate the formation of both a systemic immunological response and the formation of specific secretory immunity to human rotavirus A. Conclusion. Thus, three-time intramuscular immunization of minipigs with the Gam-VLP-rota vaccine forms stable protective humoral and cellular immunity in experimental animals. Evaluated vaccine is safe and has good local tolerability.

1 March 2019 in Biochimie
Verified
Journal Article
Closed access
NFNatalia Fedorova
Natalia Fedorova
YCYana Chernoryzh
Yana Chernoryzh
GVGalina R. Vinogradskaya
Galina R. Vinogradskaya
SESvetlana S. Emelianova
Svetlana S. Emelianova
LZLarisa E. Zavalyshina
Larisa E. Zavalyshina
Alexander V. IvanovAlexander V. Ivanov
Alexander V. Ivanov

6 May 2024 in Problems of Virology
Verified
Journal Article
Open access
PDF file
OLO E Latyshev
O E Latyshev
OZO N Zaykova
O N Zaykova
OEO V Eliseeva
O V Eliseeva
TST E Savochkina
T E Savochkina
YCYana Chernoryzh
Yana Chernoryzh
Tatiana Vladimirovna GrebennikovaTatiana Vladimirovna Grebennikova
Tatiana Vladimirovna Grebennikova
Introduction. The COVID-19 pandemic caused by SARS-CoV-2 has created serious health problems worldwide. The most effective way to prevent the occurrence of new epidemic outbreaks is vaccination. One of the modern and effective approaches to vaccine development is the use of virus-like particles (VLPs). The aim of the study is to develop a technology for production of VLP based on recombinant SARS-CoV-2 proteins (E, M, N and S) in insect cells. Materials and methods. Synthetic genes encoding coronavirus proteins E, M, N and S were used. VLP with various surface proteins of strains similar to the Wuhan virus, Delta, Alpha and Omicron were developed and cloned into the pFastBac plasmid. The proteins were synthesized in the baculovirus expression system and assembled into VLP in the portable Trichoplusia ni cell. The presence of insertion in the baculovirus genome was determined by PCR. ELISA and immunoblotting were used to study the antigenic activity of VLP. VLP purification was performed by ultracentrifugation using 20% sucrose. Morphology was assessed using electron microscopy and dynamic light scattering. Results. VLPs consisting of recombinant SARS-CoV-2 proteins (S, M, E and N) were obtained and characterized. The specific binding of antigenic determinants in synthesized VLPs with antibodies to SARS-CoV-2 proteins has been demonstrated. The immunogenic properties of VLPs have been studied. Conclusion. The production and purification of recombinant VLPs consisting of full-length SARS-CoV-2 proteins with a universal set of surface antigens have been developed and optimized. Self-assembling particles that mimic the coronavirus virion induce a specific immune response against SARS-CoV-2.

12 March 2025 in Problems of Virology
Verified
Journal Article
Open access
YCYana Chernoryzh
Yana Chernoryzh
VKValeria M. Kondratieva
Valeria M. Kondratieva
АMАnastasia P. Malkova
Аnastasia P. Malkova
TSTatyana E. Savochkina
Tatyana E. Savochkina
OEOlesya V. Eliseeva
Olesya V. Eliseeva
ЯЮЯкунин Дмитрий Юрьевич
Якунин Дмитрий Юрьевич
Introduction. The large-scale and prolonged pandemic of the novel coronavirus disease (COVID-19) has demonstrated the need for effective vaccination. Along with immunogenicity, safety is a critical issue for vaccines, as public trust can contribute to the success or failure of immunization programs. In preclinical studies, we assessed the safety of an intranasal Virus-like particle (VLP)-based vaccine in mice and rats. The aim of the study is to conduct preclinical acute and subchronic toxicity studies assessing local tolerability of an intranasal VLP vaccine against COVID-19 in accordance with good laboratory practice. Materials and methods. Study was performed on adult outbreed mice (30 males, 30 females) and rats (45 males, 45 females). Physiological, morphometric and histological parameters, as well as general and biochemical blood tests and urine analysis were assessed. Results. No deaths or intoxication were recorded in the acute toxicity study on mice, all parameters were within the physiological norm. In the subchronic toxicity study on rats, no changes in the general condition, behavior, or death of animals were noted. The structure of internal organs, blood and urine tests, hemostasis did not differ significantly between the groups. No local irritant effect was detected at the injection site during visual assessment, cytological and histological analysis. Conclusion. The VLP vaccine is safe, as evidenced by the results of preclinical studies, does not negatively affect the function of various organs, the level of cellular and biochemical biomarkers in the blood and urine of mice and rats. Visual assessment, cytology and histology of the vaccine injection site did not reveal any local irritant effect.